231 related articles for article (PubMed ID: 24829203)
1. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.
Stengel A; Schnittger S; Weissmann S; Kuznia S; Kern W; Kohlmann A; Haferlach T; Haferlach C
Blood; 2014 Jul; 124(2):251-8. PubMed ID: 24829203
[TBL] [Abstract][Full Text] [Related]
2. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.
Mühlbacher V; Zenger M; Schnittger S; Weissmann S; Kunze F; Kohlmann A; Bellos F; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 Jun; 53(6):524-36. PubMed ID: 24619868
[TBL] [Abstract][Full Text] [Related]
3. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.
Fang M; Becker PS; Linenberger M; Eaton KD; Appelbaum FR; Dreyer Z; Airewele G; Redell M; Lopez-Terrada D; Patel A; Rabin KR; Lu X
Am J Clin Pathol; 2015 Aug; 144(2):263-70. PubMed ID: 26185311
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
5. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
6. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
7. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Martín-Palanco V; Martín-Subero JI; San José-Eneriz E; Garate L; Álvarez S; Miranda E; Rodríguez-Otero P; Rifón J; Torres A; Calasanz MJ; Cruz Cigudosa J; Román-Gómez J; Prósper F
PLoS One; 2011 Feb; 6(2):e17012. PubMed ID: 21386967
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic abnormalities and TP53 and RAS gene profiles of childhood acute lymphoblastic leukemia in Morocco.
Skhoun H; El Fessikh M; El Alaoui Al Abdallaoui M; Khattab M; Belkhayat A; Chebihi ZT; Hassani A; Abilkassem R; Agadr A; Dakka N; El Baghdadi J
Arch Pediatr; 2024 May; 31(4):238-244. PubMed ID: 38679547
[TBL] [Abstract][Full Text] [Related]
9.
Comeaux EQ; Mullighan CG
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28003275
[TBL] [Abstract][Full Text] [Related]
10. TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
Yu CH; Chang WT; Jou ST; Lin TK; Chang YH; Lin CY; Lin KH; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Su YN; Hung CC; Lin DT; Chen HY; Yang YL
Cancer Sci; 2020 Jan; 111(1):229-238. PubMed ID: 31729120
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of cytogenetic findings at diagnosis and in remission in childhood and adult acute lymphoblastic leukemia: experience from India.
Amare P; Gladstone B; Varghese C; Pai S; Advani S
Cancer Genet Cytogenet; 1999 Apr; 110(1):44-53. PubMed ID: 10198622
[TBL] [Abstract][Full Text] [Related]
12. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
14. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
15. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
16. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.
Kim R; Bergugnat H; Larcher L; Duchmann M; Passet M; Gachet S; Cuccuini W; Lafage-Pochitaloff M; Pastoret C; Grardel N; Asnafi V; Schäfer BW; Delabesse E; Itzykson R; Adès L; Hicheri Y; Chalandon Y; Graux C; Chevallier P; Hunault M; Leguay T; Huguet F; Lhéritier V; Dombret H; Soulier J; Rousselot P; Boissel N; Clappier E
Blood Cancer Discov; 2023 Mar; 4(2):134-149. PubMed ID: 36630200
[TBL] [Abstract][Full Text] [Related]
17. A population-based cytogenetic study of adults with acute lymphoblastic leukemia.
Moorman AV; Chilton L; Wilkinson J; Ensor HM; Bown N; Proctor SJ
Blood; 2010 Jan; 115(2):206-14. PubMed ID: 19897583
[TBL] [Abstract][Full Text] [Related]
18. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.
Salmoiraghi S; Montalvo ML; Ubiali G; Tosi M; Peruta B; Zanghi P; Oldani E; Boschini C; Kohlmann A; Bungaro S; Intermesoli T; Terruzzi E; Angelucci E; Cavattoni I; Ciceri F; Bassan R; Rambaldi A; Spinelli O
Haematologica; 2016 Jun; 101(6):e245-8. PubMed ID: 26992948
[No Abstract] [Full Text] [Related]
19. Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia.
Piskunova IS; Obukhova TN; Parovichnikova EN; Kulikov SM; Troitskaya VV; Gavrilina OA; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):30-37. PubMed ID: 30701920
[TBL] [Abstract][Full Text] [Related]
20. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.
Gao L; Harbaugh B; Parr K; Patel P; Golem S; Zhang D; Woodroof J; Cui W
Am J Clin Pathol; 2022 Jan; 157(1):119-129. PubMed ID: 34528662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
